Axel Hoos
GlaxoSmithKline (United States) · 324 works · 42,318 citations · h-index 68
Top works
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
- Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study
- Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
- Improved Endpoints for Cancer Immunotherapy Trials
- A Clinical Development Paradigm for Cancer Vaccines and Related Biologics
- Analysis of the Prognostic Significance of Microscopic Margins in 2,084 Localized Primary Adult Soft Tissue Sarcomas
- Phase III Comparison of Vitespen, an Autologous Tumor-Derived Heat Shock Protein gp96 Peptide Complex Vaccine, With Physician's Choice of Treatment for Stage IV Melanoma: The C-100-21 Study Group
- Efficacy and safety of ipilimumab induction and maintenance dosing in patients with advanced melanoma who progressed on one or more prior therapies
- Development of Ipilimumab: Contribution to a New Paradigm for Cancer Immunotherapy
- Validation of Tissue Microarrays for Immunohistochemical Profiling of Cancer Specimens Using the Example of Human Fibroblastic Tumors
- Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
- p63 expression profiles in human normal and tumor tissues.
- CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS
- Novel efficacy criteria for antitumor activity to immunotherapy using the example of ipilimumab, an anti-CTLA-4 monoclonal antibody
- Antitumor response and new lesions in advanced melanoma patients on ipilimumab treatment
- Dose effect of ipilimumab in patients with advanced melanoma: Results from a phase II, randomized, dose-ranging study
- Continuous systemic corticosteroids do not affect the ongoing regression of metastatic melanoma for more than two years following ipilimumab therapy